Those suffering from mild heart failure can now have a sign of relief; anew Pfizer drug from Medtronic has the capacity to boost survival and reduced hospitalization.

The drug which was on the market has outlived its usefulness in dealing with the complications and a study had been conducted to see the connection between the drug and kidney complications.

The new technology was said to be safe but not effective according to the American College of Cardiology former president.

Heart failure affects million of persons on the globe and the reports are expected to have an effect on the health sector. The problem is caused by “tired and worn out” heart muscles unable to perform as expected, leaving their victims struggling for breath.

The company is based in New York and has produced Inspra, which helps in the management of the complications. Hospitalization is reduced to the persons who used the new drug over the last two years.

A University in France found out that only 19 people, in a year, are to be completely healed of heart failure related complications and 51 treated in preventing one death.

The new technology has the potential to shake the industry according to Dr. Mariell Jessup, who headed the conference.

Image Credit: